RU2316564C2 - Специфические антитела человека для избирательной терапии рака - Google Patents

Специфические антитела человека для избирательной терапии рака Download PDF

Info

Publication number
RU2316564C2
RU2316564C2 RU2003123100/13A RU2003123100A RU2316564C2 RU 2316564 C2 RU2316564 C2 RU 2316564C2 RU 2003123100/13 A RU2003123100/13 A RU 2003123100/13A RU 2003123100 A RU2003123100 A RU 2003123100A RU 2316564 C2 RU2316564 C2 RU 2316564C2
Authority
RU
Russia
Prior art keywords
peptide
molecule
polypeptide according
cells
binding
Prior art date
Application number
RU2003123100/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2003123100A (ru
Inventor
Йошевед ХАГАЙ (IL)
Йошевед ХАГАЙ
Жанет ЛАЗАРОВИЦ (IL)
Жанет ЛАЗАРОВИЦ
Рашель ГИ (IL)
Рашель ГИ
Орли ЛИПШИЦ (IL)
Орли ЛИПШИЦ
Эстер ЗАНТОН (IL)
Эстер ЗАНТОН
Авигдор ЛЕВАНОН (IL)
Авигдор ЛЕВАНОН
Даниэль ПЛАКСИН (IL)
Даниэль ПЛАКСИН
Тувиа ПЕРЕЦ (IL)
Тувиа ПЕРЕЦ
Original Assignee
Сейвиент Фармасьютикэлс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сейвиент Фармасьютикэлс, Инк. filed Critical Сейвиент Фармасьютикэлс, Инк.
Publication of RU2003123100A publication Critical patent/RU2003123100A/ru
Application granted granted Critical
Publication of RU2316564C2 publication Critical patent/RU2316564C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2003123100/13A 2000-12-29 2001-12-31 Специфические антитела человека для избирательной терапии рака RU2316564C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
RU2003123100A RU2003123100A (ru) 2005-03-10
RU2316564C2 true RU2316564C2 (ru) 2008-02-10

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003123100/13A RU2316564C2 (ru) 2000-12-29 2001-12-31 Специфические антитела человека для избирательной терапии рака

Country Status (15)

Country Link
EP (1) EP1353937A4 (enExample)
JP (1) JP2004524023A (enExample)
KR (1) KR20030091952A (enExample)
CN (1) CN100374456C (enExample)
AU (1) AU2002246737B2 (enExample)
BR (1) BR0116763A (enExample)
CA (1) CA2433227A1 (enExample)
CZ (1) CZ20031983A3 (enExample)
HU (1) HUP0400775A2 (enExample)
IL (1) IL156690A0 (enExample)
MX (1) MXPA03005944A (enExample)
NZ (1) NZ527173A (enExample)
PL (1) PL365758A1 (enExample)
RU (1) RU2316564C2 (enExample)
WO (1) WO2002059264A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
KR20060107501A (ko) * 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
BR112013000452A2 (pt) * 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
PL3590962T3 (pl) * 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CR20220578A (es) * 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Моноклональные антитела. /Под ред. Р.Г.КЕННЕТА с соавт. - М.: Медицина, 1983, с.107. *

Also Published As

Publication number Publication date
CN1551886A (zh) 2004-12-01
WO2002059264A2 (en) 2002-08-01
JP2004524023A (ja) 2004-08-12
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
EP1353937A2 (en) 2003-10-22
CZ20031983A3 (cs) 2005-07-13
WO2002059264A3 (en) 2003-03-06
KR20030091952A (ko) 2003-12-03
PL365758A1 (en) 2005-01-10
IL156690A0 (en) 2004-01-04
NZ527173A (en) 2006-03-31
BR0116763A (pt) 2004-03-09
CA2433227A1 (en) 2002-08-01
EP1353937A4 (en) 2005-04-13
RU2003123100A (ru) 2005-03-10
MXPA03005944A (es) 2005-04-29
HUP0400775A2 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
RU2317999C2 (ru) SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20240294648A1 (en) MANAbodies AND METHODS OF USING
Kriangkum et al. Bispecific and bifunctional single chain recombinant antibodies
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
IL291545B1 (en) Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof
WO2019016392A1 (en) HUMAN ANTIBODIES BINDING TO ROR2
WO2019030240A1 (en) ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
FI3433280T3 (fi) Proteaasin aktivoimia t-solubispesifisiä molekyylejä
HRP20010551B1 (hr) Humana monoklonalna antitijela za ctla-4
KR900700134A (ko) Il-2 수용체-특이적 키메릭 항체
AR035581A1 (es) Anticuerpos para il-1beta humana
RU2003133973A (ru) Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
JP2008532949A5 (enExample)
JP2005510246A5 (enExample)
CA2441845A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
BR0207151A (pt) Moléculas de aglutinação terapêuticas
US12012450B2 (en) Anti-NKG2A antibodies and compositions
MY143963A (en) Therapeutic binding molecules
WO2002059264A3 (en) Specific human antibodies for selective cancer therapy
KR101828794B1 (ko) 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체
DE10021678A1 (de) Antikörperkonstrukte mit variablen Regionen
CN106674347A (zh) 一种新型耳抑素抗体
Hombach et al. Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080101